Key facts: Italy
| Main buyers | Regional central purchasing bodies (for example ARIA, SoReSa, Intercent-ER, ESTAR, Azienda Zero); local health authorities and hospitals below the threshold |
|---|---|
| Main routes | Regional tenders by lot; framework agreements (accordo quadro), which for biosimilars include several ranked suppliers |
| Typical term | Typically 12 to 36 months; frameworks up to four years |
| Award model | Mostly lowest price, some quality-price awards; biosimilar frameworks ranked, with patients treated with one of the first three |
How are pharmaceutical tenders organised in Italy?
Each region buys through its own central purchasing body, which runs large tenders by lot for all its hospitals and local health authorities. A 2026 decree reconfirmed that medicines above €40,000 must go through these bodies or the national buyer, so regional rounds set most of the market.
What is special about Italian biosimilar tenders?
When more than three medicines share an active ingredient, the region must sign a framework with several suppliers, ranked by price, and doctors treat new patients with one of the first three. Being admitted and being ranked high are different outcomes, and a 2025 court ruling confirmed the framework must include at least the top three.
Rounds are frequent and each region publishes in its own way. Without a consolidated view it is easy to miss a round or misread a ranking.
Gara, aggiudicazione and accordo quadro: reading an Italian result
Each regional central purchasing body (centrale di committenza) publishes its gara per lot. The aggiudicazione, the award decision, usually gives the winner, the ranking and the awarded unit price per lot, which makes Italy one of the easiest markets to read once the regions are brought together.
For biosimilars the result is an accordo quadro with several ranked suppliers, so the esito shows a ranking of suppliers, and the share each supplier gets depends on its place.
How does RGS help in Italy?
We track the regional rounds, capture rankings and award prices per lot, and roll the regions up to a national view for comparing your position region by region.
What is public in Italy, and what is not
Italy is one of the more transparent markets. Notices and award results are published, usually with the awarded unit prices and the rankings.
Confidential discounts agreed with the national medicines agency and the payback mechanisms are not published, so the net price can differ from the awarded one.
Questions about Italy
How are biosimilars tendered in Italy?
Through regional framework agreements with several suppliers, ranked by price, whenever more than three products share the active ingredient. New patients are treated with one of the first three ranked.
Are Italian tender prices published?
Usually yes. Award results generally include the awarded unit prices and rankings. Confidential national discounts are not published.
Where can I find the esiti of a gara farmaci?
In the award decision (determina di aggiudicazione) and the esito published by each regional central purchasing body, which normally list the winner per lot, the ranking and often the unit price. RGS collects them across all regions into one view per molecule.
Can RGS show confidential contracts and prices in Italy?
No outside service can, because they are never published. RGS covers what buyers publish. For the confidential part we set up a private pipeline for your company: your own bids, results, buyer correspondence and price lists, loaded next to the public data and visible only to your team.